Physician profile
Hannah Anzalone
NPI 1730793787
$1,314.32
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $994 · 2022: $272 · 2024: $48.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $48.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $48.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $324.44 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $157.16 | 2021 | |
| Abbvie INC. | $153.74 | 2021 | |
| Neurelis, INC. | $146.07 | 2021 | |
| Sk Life Science, INC. | $82.95 | 2021 | |
| Lilly USA, LLC | $69.30 | 2021 | |
| Ucb, INC. | $47.20 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $45.12 | 2021 | |
| Acadia Pharmaceuticals INC | $39.00 | 2021 | |
| Biogen, INC. | $37.50 | 2021 | |
| Amgen INC. | $34.33 | 2024 | Uplizna |
| Astrazeneca Pharmaceuticals LP | $30.07 | 2021 | |
| Boston Scientific Corporation | $24.33 | 2021 | |
| Medtronic, INC. | $23.26 | 2021 | |
| Greenwich Biosciences, INC. | $21.63 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.00 | 2021 | |
| Astellas Pharma US INC | $14.20 | 2024 | Veozah |
| Amneal Pharmaceuticals LLC | $13.69 | 2021 | |
| Dexcom, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Anzalone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.